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Abstract
Cycling stage races are strenuous endurance events during which exercise-induced variations in hematological parameters
are consistently observed. However, specific literature on such changes is scarce and published data have been derived
from small samples of athletes. The aims of this study were: (1) to determine the hematological response to middle-term
strenuous endurance; and (2) to determine whether a relationship exists between the athlete-specific hematological profile
and final placement in a cycling stage race. The study population was male professional cyclists (n = 253) competing in the
2010 (n = 144) and 2012 (n = 109) GiroBio 10-day stage races. Blood draws taken before the start of the race, at mid-race, and
at end-race were performed in strict compliance with academic and anti-doping pre-analytical warnings. Blood chemistry
included white blood cell, red blood cell, hemoglobin concentration, hematocrit, mean corpuscular volume (MCV), mean
hemoglobin content (MCH), mean corpuscular hemoglobin content (MCHC), platelets, and reticulocyte relative and
absolute counts. Compared to baseline values, erythrocyte, hemoglobin, hematocrit, MCHC, platelet and reticulocyte counts
were all consistently lower at mid-race, but returned to normal by race-end, while leukocytes were increased in the final
phase. MCV increased during both events. MCH increased in the first part to then return to baseline in the 2012 race. The
calculated OFF-score consistently decreased in the first half of the race before increasing, but remained lower than the
baseline value. The trends of variation in hematological parameters were substantially similar in both events. There was an
inverse, albeit weak, relationship between placement and erythrocyte, platelet, hemoglobin, hematocrit and OFF-score
values in the 2010, but not in the 2012 race. In conclusion, the data confirm that, in this large series of elite road cyclists, the
strenuous effort a rider sustains during a stage race induces appreciable changes in the hematological profile.
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Introduction
Cycling stage races are among the most strenuous of endurance
events. The exercise-induced variations observed in hematological
parameters appear to be consistent with the rider’s physiological
response to maintain and improve highly demanding performanc-
es day-after-day [1,2]. During training and competition, an
essential part of evaluating the health and performance of
professional and recreational athletes is periodic assessment of
the hematological profile. Together with evaluation of iron
metabolism, serial blood chemistry analysis can point to whether
an out-of-range shift in blood parameters may be attributable to
the response to physical effort or to an index of abnormal response
[3,4,5].
Despite media exposure of doping scandals and subsequent
disciplinary action taken by sports organizations against cheating
athletes, efforts to restore cycling’s tarnished reputation have been
thwarted by the illicit conduct of individual athletes; sometimes
acting with their physician’s complicity. Being an endurance sport,
cycling is pervaded by the use of ever more sophisticated doping
procedures that increase oxygen delivery to muscles. Erythropoi-
esis-stimulating agents and autotransfusion have been the most
frequently detected performance-enhancing substance and proce-
dures [6].
A starting point for determining irregular and suspect behavior
in athletes is a better appreciation of the hematological response to
vigorous physical activity. This is of particular interest in the
context of the Athlete’s Biological Passport (ABP), which was
devised to detect abnormal variation(s), even at a single time-point,
versus a subject-specific physiological range deduced from the
athlete’s own previous data [7,8]. Because the variations during a
competitive season affect the behavior of hematological parame-
ters over a season, knowing their variability could help to define
the physiological ranges in an athlete [4].
The GiroBio, held in mid-June every year in northern Italy, is
the ‘‘under-27 s amateur Giro d’Italia’’, a surrogate for the Giro
d’Italia and other international road races (Tour de France, Vuelta
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a Espana) for young cyclists. It attracts more than 150 professional
cyclists from all over the world annually. Since 2005 it has been
included in the Union Cycliste Internationale (UCI) Europe Tour
circuit, category 2.2. About half the duration of its major
counterpart, the GiroBio format is 10 stages over 11 days. The
GiroBio race represents the entry step to a fully professional career
for most cyclists. The race aims to promote the values of sport and
fair play in healthy competition, counteracting the doping culture,
through the adoption of innovative organizational aspects, as
discussed below.
To our knowledge, few studies have analyzed the hematological
profile of cyclists competing in a cycling stage race. All prior
studies had small populations, mainly from one or two teams,
because of the difficulties inherent in organizing such an
evaluation by a non-official, anti-doping agency. Recent findings
reported by our own group demonstrated that major metabolic
modifications in homeostasis, systemic and organ and tissue-
specific, occurred in response to the metabolic effort cyclists
sustained during the 3-week Giro d’Italia stage race [9].
In this study, we evaluated the hematological profiles of 253
elite cyclists competing in the 2010 and 2012 GiroBio races. The
aims were; (1) to define a general trend in the variations of the
hematological parameters, including those relevant for anti-doping
purposes, in response to middle-term strenuous endurance; and (2)
to determine whether a relationship between the athlete-specific
profile and final placement in both race events is present.
Materials and Methods
Ethics Statement
The study was approved by the National Commission on
Health Protection [Commissione Nazionale Tutela della Salute],
the Italian Cycling Federation [Federazione Ciclistica Italiana,
Rome, Italy] and the Department for Youth Policy and Sport –
Presidency of the Council of Ministers [Dipartimento per le
politiche giovanili e le attivita` sportive - Presidenza del Consiglio
dei Ministri, Rome, Italy]. The team participation was on a
voluntary basis upon a request to the organizers. Nevertheless,
race participation required the cyclists and team staffs to follow the
competition’s organizational model. Sanction for any infractions of
the competition rules was the disqualification from the race of the
cyclists and/or team. A written informed consent for using the
data collected during the race for research purposes was signed by
all subjects. The clinical investigations were conducted according
to the principles expressed in the Declaration of Helsinki.
Study Population
Of the 346 male professional cyclists competing in the 2010 and
2012 GiroBio events and recruited for this study, 253 riders
completed the race and had blood drawn. The present analysis
included only the data for the subjects from whom all three blood
samples were collected: 144 out of 178 riders competing in the
2010 GiroBio, and 109 out of 168 riders competing in the 2012
GiroBio. The mean age of the riders in the 2010 GiroBio was
21.861.7 years and 22.361.6 years in the 2012 GiroBio. Nineteen
riders competed in both the 2010 and 2012 races.
Both GiroBio events were held, as usual, in mid-June; the total
length covered was 1,276.9 km in 2010 and 1,351.5 km in 2012.
The difference in elevation for each stage was calculated from the
point-by-point sum of the difference in altitude. The main features
of each stage of the two races are illustrated in Table 1.
On the basis of an innovative organizational and managerial
model for the race, all riders stayed in the same accommodations,
they received the same diet (about 5,700 kcal per day per rider,
composed of 15% protein, 24% lipids and 61% carbohydrates)
and standardized medical care and dietary supplementation
between meals were also provided, in compliance with health
and safety protection rules as established by Italian law. Finally, all
the riders were followed by the same medical-scientific team.
Assessment of Hematological Profile
Under the provisions of the race regulations, participants’ health
status was assessed by blood testing prior to the start of the race,
halfway through the race and at the end; that is, at day -2 (T1), day
6 (T2), and day 10 in the 2010 event, and day 9 in the 2012 event
(T3). The academic-accepted pre-analytical warnings [10] and
official rules of the World Anti-Doping Agency (WADA) [11] and
Union Cycliste Internationale (UCI) [12] concerning blood sample
collection and sample transport were strictly followed. Briefly,
standard blood draws were taken in the morning between 0800
and 1000 h, after overnight fasting; after awakening, the riders
rested in a sitting position for at least 10 minutes with feet on the
floor before blood was drawn [11]. Blood was collected into
3.5 mL evacuated tubes coated with K2EDTA (BD Vacutainer
Systems, Becton–Dickinson, Franklin Lakes, NJ, USA). Immedi-
ately after drawing, the tubes were inverted ten times and stored at
4uC in a temperature-controlled portable electric refrigerator, and
then transported by car to the laboratory for analysis. Despite the
distance between sampling site and laboratory, the time between
sampling and analysis was always less than 12 hours. On arrival at
the laboratory, the K2EDTA-anticoagulated blood was homoge-
nized for 15 min prior to analysis, in compliance with UCI and
WADA recommendations [11,12].
Blood chemistry included: white blood cell count (WBC 109/L);
red blood cell count (RBC 1012/L); hemoglobin concentration
([Hb], g/L); hematocrit (Ht, %); mean corpuscular volume (MCV,
fL); mean hemoglobin content (MCH, pg); mean corpuscular
hemoglobin content (MCHC, g/L); platelet count (Plt, 109/L);
reticulocyte relative count (Ret%, %); and reticulocyte absolute
count (Ret#, 1012/L). Analyses were performed on a Sysmex XE
2100 (Sysmex, Kobe, Japan); the imprecision of the hematological
tests was ,1.5%, except for Ret% which has an imprecision
,15.0%. Internal quality controls were performed by the means
of e-Check (LE Tri level, Sysmex, Kobe Japan). Instrumentation
was also controlled during the study period by external proficiency
testing.
Statistical Analysis
The OFF-hr score (OFF-score) was calculated as follows [13]:
OFF-score = [Hb] - 60!Ret%.
with [Hb] expressed as g/L. This score is used to detect blood
doping; for example, an OFF-score higher than 110 indicate a
probability of 99.9% that blood manipulations have been carried
out, even many weeks before.
Statistical analysis was performed using SPSS version 14.0
(SPSS Inc., Chicago, IL, USA). Normal distribution of values was
tested using the Kolmogorov-Smirnov normality test; in the
descriptive analysis, all normally distributed values are expressed
as the means 6 SD while data from non-normal distributions are
expressed as the median and the distribution range. A repeated
measures one-way analysis of variance (ANOVA), with Bonferro-
ni’s correction for post-hoc analysis, was used to compare normal
data over time; Friedman’s test with Dunn’s correction for post-
hoc analysis was used to compare data from non-normal
distributions over time. Wilcoxon’s matched pairs test was used
to compare the values for each time-point in the two races.
Correlations among hematological parameters and between
hematological parameters and ranking were examined using
The GiroBio: Elite Cyclists Haematological Profile
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Spearman’s rank correlation coefficient. Furthermore, to detect
differences in the hematological profile in relation to the final
ranking, the profiles of the cyclists completing the race in the first
30 positions were compared with those of the last 30 positions: t-
tests were used to compare each time-point, for each parameter,
between the two groups and to compare the differences, ‘‘D’’,
between T2 and T1, T3 and T2 and T3 and T1, between the two
groups. The significance level was set at 0.05.
Results
Variations between Races
Comparison of the data from the two races showed consistent
changes in the riders’ hematological profile. WBC increased only
in the second half, while RBC, Hb, Ht and Plt decreased in the
first half before increasing thereafter. Hb decreased by about 8.5%
at T2, 4.3% at T3 versus T1. MCV increased and MCHC
decreased; only MCH constantly increased during the 2010 race,
while it first increased and then decreased during the 2012 event.
The results are summarized in Figure 1.
The data from both races showed a U-shaped trend in
reticulocyte count. Ret% decreased by about 6% from T1 to T2
and then increased by about 14.5% at T3, as averaged between
the two races. Accordingly, the Ret absolute number significantly
decreased by about 18.5% in the first half of the race and then
increased by about 29.5% thereafter. In general, the calculated
OFF score followed the same trend as the other hematological
parameters. The results of Ret count and OFF-score are reported
in Figure 2.
In order to define the physiological significance of the time-
dependent variations, the theoretical intra-individual variability
(CVBw) [14,15] and the percentage change were compared for
each parameter, as obtained by the paired comparison of the time-
points (T2 vs. T1, T3 vs. T2 and T3 vs. T1). As shown in Table 2,
comparison of subject-specific modifications reveals a very high
number of riders with intra-individual variations exceeding the
theoretical values.
Comparison between the Two Races
Paired comparison of the same time-points in the two races
revealed important differences. Taking the 2010 event as
reference, the data from the 2012 race showed lower WBC
counts at T1 and T3, but not in RBC, Plt or MCH. Hb and
MCHC were both higher at T2 and lower at T3; Ht was higher at
T1 and T2 but lower at T3. MCV was always higher (Figure 1).
The Ret counts were higher in 2012 than in 2010, except for
Ret# at T3, which did not differ. Because of the differences in Hb
and Ret%, the OFF-scores were significantly higher at all time-
points in 2012 (Figure 2).
The differences in these comparisons aside, the trend for each
parameter was generally similar. However, some exceptions were
found when statisitical significance was considered: MCH
remained constant in the first half of the 2010 race and increased
thereafter, while it rose in the first half and then decreased in the
2012 event.
Correlation between Hematological Parameter Values
and Ranking
Spearman’s rank correlation analysis highlighted significant
correlations between the riders’ final finishing positions and the
value of some of the parameters in the 2010 event alone. At the
end of the 2010 race, the RBC count, Hb concentration and Ht
were inversely, albeit weakly, related with finishing position
(r =20.27, r =20.27, r =20.29, respectively; p,0.01), as were
the Plt count (r =20.27; p,0.01) and the OFF score (r =20.29;
p,0.001). That is, the higher the finishing position, the higher the
values of the analyzed parameters. These relationships were
completely lost in the 2012 race.
Comparison of the values recorded for the cyclists ranked in the
first 30 and last 30 positions at each time-point revealed
significantly higher values in the best compared to the worst
performers for: RBC count, [Hb], Ht, Plt count, and OFF-score
(0.001,p,0.05). However, in the 2012 event, only the Ht values
at T2 and at T3 were higher (p,0.05) in the best- versus the
worst-ranked riders. Finally, no significant differences were found
between the ‘‘D’’ (T2 vs. T1, T3 vs. T2 and T3 vs. T1) of the two
groups in both races.
Discussion
The widespread use of banned performance-enhancing sub-
stances and practices in elite-level cycling produces many
headlines. With the stricter enforcement of anti-doping regulations
(i.e., in- and out-of competition testing, legal action), however, the
consensus is that attitudes have changed and that, though still
present, doping is less common now than in the recent past [16].
The promotion of ethical values and the protection of athletes’
health must be the primary objectives in sports medicine [17].
Current knowledge of sports physiology and doping biomarkers
is formalized in the Athlete Biological Passport (ABP) program: an
algorithm tracking the longitudinal record of hematological
parameters as a means to define an individual’s hematological
profile and thereby identify potential deviations [17]. The central
concept of the ABP is that a better appreciation of the
physiological changes in the hematological profile related to
training, competition, and altitude will allow discrimination of
variations induced by illicit practices from those due to homeo-
static response to physical activity [18]. The aim of our study was
to add new information about the physiological response during a
multiday cycling competition (stage race). To our knowledge, this
is the first study to report the hematological variations in a large
series of professional cyclists competing in two years of the same
cycling stage-race.
In the last few years, the increasing number of published studies
on variations in hematological parameters in elite athletes reflects
the growing interest in the athlete’s physiological response to
strenuous metabolic effort, especially in the context of the current
debate on blood doping and the ABP [3,19,20]. However, few
papers have focused on the physiological response to effort in
cyclists and all of these studies involved small populations of elite
athletes; mainly from one or two teams [9].
In a recently published study, in which 9 professional cyclists
were followed over the 21-day 2011 Giro d’Italia stage-race, the
authors highlighted that RBC, Hb and Ht decreased from baseline
to the first half of the race before partially recovering, or
‘‘stabilizing’’, by the end of the competition. No significant change
in reticulocyte percentage was observed, although an upward
trend was noted. No significant variation in any of the other
parameters was recorded [9].
Previous studies have reported a decreasing trend in Hb and Ht
over brief stage races [21] or during a part of long stage races (up
to the 11th day) [22,23], but these modifications were explained by
the hemodilution that occurred during the race, which is a typical
feature of endurance activity. Although erroneously reported in
the original paper [9] and then subsequently corrected [24], after
suggestions made by Gore et al. [25], Corsetti and colleagues did
not find any significant, and univocal, changes in plasma volume.
The GiroBio: Elite Cyclists Haematological Profile
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The authors attributed the modifications in Hb and Ht to the
metabolic effort in which athletes were engaged [9].
During the 1984 Tour de France, 9 cyclists showed no variation
in Hb and Ht measured thrice weekly [26], while Hb was stable in
the first 10 days and decreased after 20 days in 15 cyclists
competing in the Giro d’Italia [1]. In contrast, Hb was found to
decrease at days 12 and 18, versus the pre-race values, in 9 cyclists
during the 2007 Tour de France [2].
And while previously published studies reported analytical test
results, none described the schemes for blood drawing, transport
and storage, all of which can potentially affect the results [10].
Only in our previous work [9] was it stated that the blood samples
were obtained and analyzed strictly following procedures and
recommendations by official anti-doping agencies [11,12]. Be-
cause the ideal conditions for correctly obtaining biological
specimens were fulfilled in that study, it is used as a reference
for the present discussion.
Figure 1. Hematological profile trends during the two races. The figure shows the trends of white blood cells (WBC), red blood cells (RBC),
hemoglobin concentration ([Hb]), hematocrit (Ht), mean corpuscular volume (MCV), mean hemoglobin content (MCH), mean corpuscular
hemoglobin concentration (MCHC), platelets (Plt) during the 2010 (black N and solid line, n = 144) and the 2012 (grey & and dotted line; n = 109)
races. The thinner lines (solid for 2010 and dotted for 2012) represent the 5th–95th percentile for WBC, MCV, MCH and MCHC, while for RBC, [Hb], Ht
and Plt they represent the 95% confidence intervals. The asterisks (*) indicate significant differences between different time-points in the same race
(*: p,0.05; **: p,0.01; ***: p,0.001). # indicates that the value of the time-point in the 2012 race is significantly different from that recorded in the
2010 event (##: p,0.01, ###: p,0.001).
doi:10.1371/journal.pone.0063092.g001
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In the present study, we studied the modifications of blood
parameters in a routine hematological profile in two large cohorts
of elite cyclists, under 27 years of age, competing in the 2010 and
2012 GiroBio cycling stage races. To our knowledge, this cohort
comprising a total of 253 subjects is the largest ever studied in
cycling to date. Our main findings reside in the confirmation of
previously reported trends [9]: RBC counts, Hb concentrations
and Ht showed a consistent decrease during the first half of the
race, versus resting values, and a subsequent recovery by the end
of the competition. The same trend was observed for platelet
count, while the WBC count was increased only in the final phase
of the race, contrary to what was reported in the previous work
[9]. Moreover, while Corsetti did not find any variation in the
other parameters, we observed an increase in MCV and a convex
trend for MCHC. Instead, MCH showed a constant increase in
the 2010 event, but an initial increase followed by a return to
baseline in the 2012 race.
Reticulocyte counts followed the same trend as that of RBC, Hb
and Ht, in contrast to the previous study in which Ret% showed a
rising, though not significant, trend. Schumacher and coworkers
found that a short bout of 30–45 minutes of exhaustive exercise
(treadmill or cycloergometer) induced, on average, a 0.5% increase
in Ret% measured 10 minutes after the exercise in nearly all male
and female endurance athletes. This trend was inverted after a
prolonged period of intensive exercise, over the competitive
season, with a decrease in Ret% of 0.1% [27].
In recent years, multivariate statistical models have been
validated as reliable approaches to detect recombinant human
erythropoietin (r-huEPO ) during current use (ON-model), as well
as after recent use (OFF-model) [13]. Later research has focused
only on the OFF-model, which is based on Hb concentrations and
Ret%, because it has been claimed able to specifically detect
recent blood doping practices, that are more likely to be
discovered in unannounced anti-doping or intra-competition
testing [28,29]. Because of the variations in Hb and Ret%, the
calculated OFF-score showed a consistent decrease from the
resting value to T2 and a slight increase towards T3, however, still
lower than the baseline value.
From a medical point of view, despite the statistical significance
of some variations, not all of them necessarily play a physiolog-
ically relevant role. Indeed, it is unlikely that the significant
variations observed in WBC (12–14%), MCV (0.2–1.0%), MCH
(0.5–1.0%), MCHC (1.0–3.0%), and Plt (3.9–8.1%) have any
physiological importance. On the other hand, the variation in
RBC, Hb, Ht, and Ret count indicated noticeable adaptive
modifications in the bone marrow microenvironment in response
to the elevated metabolic demand. Similar Ret % behaviors were
observed in cyclists during altitude training [3,30,31,32].
Importantly, the changes in the most relevant parameters (both
statistically and physiologically) often fell outside the range of
biological variability, in terms of intra-individual variability
[14,15]. When we analyzed the percentage variations of the
parameters for paired time-points, we found a very high number of
subject-specific variations exceeding the established intra-individ-
ual variability. This finding confirms the hypothesis that vigorous
metabolic effort effectively modified the hematological profile in
these cyclists.
There were no evident discrepancies between the 2010 and the
2012 GiroBio events. While they tended to overlap, some
differences did emerge between the two races when the riders’
final finishing position was correlated with the level of each
parameter. In the 2010 race, inverse relationships, even though
weak, were found between placement and RBC and Plt counts,
Hb, Ht and OFF-score. This finding indicates that the athletes
who achieved better positions had higher values, for those
parameters. However, no such relationships were observed during
the 2012 race. To confirm this possible relationship between
finishing position and specific features of the hematological profile,
we arbitrarily chose to compare the first 30 riders with the last 30.
This was done to distinguish two cohorts (corresponding to about
one fourth and one third of the total number of recruited subjects
in the two race events, respectively) that could theoretically be
considered different on the basis of clearly different results. When
the values of each time-point between the first 30 riders and the
last 30 were compared, the values of RBC, [Hb], Ht%, Plt and
OFF-score were higher in the top group in the 2010 race, while
only Ht% was found to be higher in the first versus the last riders
in 2012. Taken together, these findings confirm the notion that, at
least in endurance sports, a higher potential for oxygen transport
Figure 2. Reticulocyte counts and OFF-score trends during the
two race events. The figure shows the trends of Ret relative count
(Ret%), Ret absolute number (Ret#) and OFF-score during the 2010
(black N and solid line, n = 144) and the 2012 (grey& and dotted line;
n = 109) races. The thinner lines (solid for 2010 and dotted for 2012)
represent the 5th–95th percentile for Ret% and Ret#, while for the OFF-
score they represent the 95% confidence intervals. The asterisks (*)
indicate significant differences between different time-points in the
same race (*: p,0.05; **: p,0.01; ***: p,0.001). # indicate that the
value of the time-point in the 2012 race is significantly different from
that recorded in the 2010 event (##: p,0.01, ###: p,0.001).
doi:10.1371/journal.pone.0063092.g002
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(higher [Hb], RBC and Ht) is associated with improved
performance [6]. Moreover, except for the climatic condition
(similar in the two races), comparison of the characteristics of each
event revealed some potentially pertinent differences: the total
difference in altitude in the 2010 event was about 12,479 m in the
first five stages (the first half of the race) versus 9,923 m in 2012.
Furthermore, the third blood sample was drawn the day after the
hardest stage in 2010, while in 2012 it was performed the day
before the hardest stage. Hence, the differences in hematological
behavior might also be attributed to the features of the race routes
in addition to other, as yet undefined, factors.
Finally, the choice of the 2010 and 2012 events, but not the
2011 race, was dictated by the failure to hold blood collection in
2011. It should be noted that all the participants in the
competitions were enrolled in the study, in keeping with the
requirement of mandatory blood sampling carried out in the
context of health status control. However, the analysis in this study
was carried out using only the data derived from those subjects
from whom all three blood samples were obtained. Therefore, the
study population was not preselected.
The main limitation of the present study is that we cannot be
absolutely sure that, despite all efforts to prevent it, blood doping
may still have occurred. The pervasive use of illicit performance-
enhancing substances and practices in cycling makes such
suspicion warranted. In the GiroBio race, however, a major
deterrent to the use of doping was the provision of common
housing for all participants and the support of an independent
medical team. Another possible limitation is that we studied the
Hb concentration, whereas a recent study demonstrated that
hemoglobin mass (Hbmass) measurements may be more useful.
Indeed, the aim of most blood doping practices is to increase total
Hbmass. Garvican and colleagues showed that, in contrast to Hb
and Ht, the Hbmass (measured via the CO-rebreathing test
performed on location during a professional cycling tour)
remained stable over 6 days. This finding indicates that Hbmass
has greater utility in ABP evaluation [33].
In conclusion, we found that, as compared to rest values, RBC,
Ret and Plt counts, as well as Hb and Ht, all decreased after the
first part of the race, before recovering at the end of the race in
professional cyclists competing in two 10-day cycling stage races.
The same trend was observed for the OFF-score. Finally, RBC,
Hb, Ht and OFF-score values were inversely related to the riders’
final finishing position, though only in one of the two races. This
finding confirms that the best performances are, at least in part,
associated with higher potential for oxygen transport in blood.
These data could be useful for defining a typical haematological
profile that, in turn, can be used for identifying possible deviations
caused by pathologies and abuse of illicit substances, or both. In
fact, few papers have described, in a standardized way, the
haematological behavior of athletes during such races. Moreover,
international agencies, engaged in testing for blood doping have
not released the values obtained from either negative- or positive-
tested athletes. Thus, it is difficult to evaluate a regular profile
based only on common haematological parameters. We acknowl-
edge that further research in this area, together with the
publication of haematological data from large cohorts of
professional athletes, especially cyclists during competitions, is
required to improve data interpretation in anti-doping evaluation.
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